ASCO 2024 | Treatment options for patients with metastatic castration-resistant prostate cancer

Christos Kyriakopoulos • 2 Jun 2024

ASCO 2024

CHAARTED2

Christos Kyriakopoulos, MD, University of Wisconsin, Madison, WI, reflects on the findings of the CHAARTED2 trial (NCT03419234) and evaluates the optimal treatment strategies for patients with metastatic castration-resistant prostate cancer (mCRPC). For chemotherapy-ineligible patients, the recommendation is to initiate treatment with docetaxel. Additionally, it is crucial to identify any mutations that could qualify patients for PARP inhibitor therapy. In contrast, patients with castration-sensitive prostate cancer (CSPC) are eligible for second-line chemotherapy options such as cabazitaxel and 177Lu-PSMA-617. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Stock and Other Ownership Interests – Biogen; Epic Systems (I)
Consulting or Advisory Role – AVEO; EMD Serono; Exelixis; Janssen Oncology; Janssen Oncology; Sanofi
Research Funding – AstraZeneca; ESSA; Gilead Sciences; Pionyr; Sanofi